SleepWell Trade

Trend-Following Backtester · Guide · backtest 한국어

equity · US

Regencell Bioscience Holdings Limited backtest

10 trend-following strategies were compared on the full daily history of Regencell Bioscience Holdings Limited. 6 beat buy-and-hold CAGR; ADX / DI 방향성 ranks first by Sharpe, matching the main backtester.

Data 2021-07-16 ~ 2026-07-31daily bars 1,266 (5.0 years)Costs 0.5%Venue XNASMonthly snapshot 2026-07-31

Results by strategy

6 of 10 beat buy and hold (CAGR 85.0%, drawdown -93.9%).

Sharpe leader (same as main): ADX / DI 방향성 — CAGR 204.1%, MDD -86.7%, Sharpe 1.08, 13% exposure.

No strategy retained at least 75% of buy-and-hold CAGR while reducing drawdown by both 20% relatively and 5 percentage points absolutely.

The alternative must retain 75% of buy-and-hold CAGR, improve drawdown by at least 20% and 5 percentage points, and stay below 95% exposure; the ranking weights return retention 60% and drawdown improvement 40%.

Strategy · parametersCAGRMDDSharpeCalmarTotalTradesExposure
ADX / DI 방향성
period=39, threshold=41
204.1%-86.7%1.082.35272.2x413%
Donchian 채널 돌파
entryN=11, exitN=100
120.7%-90.6%1.021.3354.1x1484%
Supertrend
period=24, mult=4.3
123.0%-92.8%0.951.3357.0x2434%
EMA 크로스오버
fast=39, slow=68
93.6%-86.7%0.941.0827.9x1240%
MACD
fast=18, slow=35, signal=18
129.5%-81.7%0.931.5865.8x4744%
Keltner 채널 돌파
emaPeriod=38, atrPeriod=11, mult=3.9
108.4%-79.2%0.911.3740.5x68%
SMA 크로스오버
fast=17, slow=102
81.0%-86.7%0.890.9319.9x1833%
ROC 모멘텀
n=70, threshold=0.11
73.8%-88.1%0.880.8416.2x3635%
볼린저 밴드 돌파
n=35, k=2.8
81.1%-84.0%0.850.9720.0x1012%
Parabolic SAR
step=0.025, maxStep=0.34
64.6%-92.7%0.840.7012.3x9340%
Buy and hold85.0%-93.9%1.000.9122.2x1100%
1x 10x 100x 1,000x 2022 2023 2024 2025 2026 ADX / DI 방향성Buy and hold
ADX / DI 방향성: Solid strategy line versus dashed buy-and-hold line. Log scale.
0% -23% -47% -70% -94% 2022 2023 2024 2025 2026 Buy and holdADX / DI 방향성
ADX / DI 방향성 maximum drawdown -86.7% (2025-06-17 → 2025-07-02), prior peak not yet recovered.

Rules of the top strategy

Looks at both the direction and the strength of the trend; holds only in a strong uptrend.

Method and caveats

Past performance does not guarantee future returns. Parameters were selected on the same full-history sample using sharpe over 40 trials per strategy, so results contain in-sample bias. 0.5% trading costs are included; taxes, slippage and rejected orders are not.
Re-run the same setupMore US assetsAll asset reports

Read next